Antibody framework residues affecting the conformation of the hypervariable loops.

Rodent monoclonal antibodies have been "humanized" or "reshaped" for therapy by transplanting the antigen-binding loops from their variable domains onto the beta-sheet framework regions of human antibodies. However, additional substitutions in the human framework regions are sometimes required for high affinity antigen binding. Here we describe antigen binding by a reshaped antibody derived from the mouse anti-lysozyme antibody D1.3, and several variants in which point mutations had been introduced into framework positions to improve its affinity. The affinities were determined from the relaxation kinetics of reactant mixtures using quenching of fluorescence that occurs upon formation of the antibody-antigen complex. The dissociation constant of lysozyme ranged from 3.7 nM (for D1.3) to 260 nM. Measurement of antibody-antigen association kinetics using stopped-flow showed that D1.3 and most of the reshaped antibodies had bimolecular rate constants of 1.4 x 10(6) s-1 M-1, indicating that differences in equilibrium constant were predominantly due to different rates of dissociation of lysozyme from immune complexes. Mutations in a triad of heavy chain residues, 27, 29 and 71, contributed 0.9 kcal/mol in antigen binding free energy, and a Phe to Tyr substitution of light chain residue 71 contributed an additional 0.8 kcal/mol. The combined effect of all these mutations brought the affinity of the reshaped antibody to within a factor of 4 of D1.3. All of these substitutions were in the beta-sheet framework closely underlying the complementarity-determining regions, and do not participate in a direct interaction with antigen. The informed selection of residues in such positions may prove essential for the success of loop transplants in antibodies. Variation of these sites may also have a role in shaping the diversity of structures found in the primary repertoire, and in affinity maturation.

[1]  C. Milstein,et al.  Reshaping human antibodies: grafting an antilysozyme activity. , 1988, Science.

[2]  G Scalise,et al.  Letter: Australia antigen in urine. , 1973, Lancet.

[3]  A Tramontano,et al.  Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. , 1990, Journal of molecular biology.

[4]  V. Pascual,et al.  Human immunoglobulin heavy-chain variable region genes: organization, polymorphism, and expression. , 1991, Advances in immunology.

[5]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[6]  K. R. Ely,et al.  Structure of a lambda-type Bence-Jones protein at 3.5-A resolution. , 1972, Biochemistry.

[7]  E. Kabat,et al.  ATTEMPTS TO LOCATE COMPLEMENTARITY‐DETERMINING RESIDUES IN THE VARIABLE POSITIONS OF LIGHT AND HEAVY CHAINS * , 1971, Annals of the New York Academy of Sciences.

[8]  E. Padlan,et al.  A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. , 1991, Molecular immunology.

[9]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[10]  C. Milstein,et al.  [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .

[11]  T. Bhat,et al.  Crystallographic refinement of the three-dimensional structure of the FabD1.3-lysozyme complex at 2.5-A resolution. , 1991, The Journal of biological chemistry.

[12]  R. Mulligan,et al.  Expression of a bacterial gene in mammalian cells. , 1980, Science.

[13]  E. Unanue,et al.  Specificity of the T cell receptor: two different determinants are generated by the same peptide and the I-Ak molecule. , 1985, Journal of immunology.

[14]  M. Smith,et al.  Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. , 1982, Nucleic acids research.

[15]  E. Getzoff,et al.  Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. N. Bhat,et al.  Small rearrangements in structures of Fv and Fab fragments of antibody D 1.3 on antigen binding , 1990, Nature.

[17]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[18]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[19]  A. Bothwell,et al.  A limited number of B cell lineages generates the heterogeneity of a secondary immune response. , 1987, Journal of immunology.

[20]  P. Leder,et al.  Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Poljak,et al.  Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodies. , 1987, Molecular immunology.

[22]  J. A. Rupley,et al.  Fluorescence of lysozyme: emissions from tryptophan residues 62 and 108 and energy migration. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.

[24]  T. Honjo,et al.  Structure of human immunoglobulin gamma genes: implications for evolution of a gene family , 1982, Cell.

[25]  G. Air,et al.  Crystal structures of neuraminidase-antibody complexes. , 1989, Cold Spring Harbor symposia on quantitative biology.

[26]  G. Cohen,et al.  The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. L. Duuren Solvent Effects in the Fluorescence of Indole and Substituted Indoles1 , 1961 .

[28]  G. Hale,et al.  Monoclonal-antibody therapy in systemic vasculitis. , 1990, The New England journal of medicine.

[29]  G Goldstein,et al.  The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. , 1975, Biochemistry.

[30]  M. Neuberger Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells. , 1983, The EMBO journal.

[31]  R. Lathe,et al.  New versatile cloning and sequencing vectors based on bacteriophage M13. , 1983, Gene.

[32]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[33]  E. Haber,et al.  Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Bruccoleri,et al.  Computer analysis of mutations that affect antibody specificity , 1990, Proteins.

[35]  T. T. Wu,et al.  AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.

[36]  A. Ciechanover,et al.  Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. , 1980, The Journal of biological chemistry.

[37]  G. M. Griffiths,et al.  Molecular events during maturation of the immune response to oxazolone , 1985, Nature.

[38]  G. Winter,et al.  Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Vieira,et al.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. , 1982, Gene.

[40]  R. Poljak,et al.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution , 1986, Science.

[41]  M. Neuberger,et al.  A hapten-specific chimaeric IgE antibody with human physiological effector function , 1985, Nature.

[42]  C. Milstein,et al.  Three‐dimensional structure determination of an anti‐2‐phenyloxazolone antibody: the role of somatic mutation and heavy/light chain pairing in the maturation of an immune response. , 1990, The EMBO journal.

[43]  H. Waldmann,et al.  REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H , 1988, The Lancet.

[44]  D. Allen,et al.  Antibody engineering for the analysis of affinity maturation of an anti‐hapten response. , 1988, The EMBO journal.

[45]  J. Maizel,et al.  Evolution of human immunoglobulin kappa J region genes. , 1982, The Journal of biological chemistry.

[46]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Geraldine Taylor,et al.  Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo , 1991, Bio/Technology.

[48]  R. Poljak,et al.  Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Milstein,et al.  Somatic mutation and the maturation of immune response to 2-phenyl oxazolone , 1984, Nature.

[50]  H. Zachau,et al.  Correct transcription of an immunoglobulin κ gene requires an upstream fragment containing conserved sequence elements , 1984, Nature.

[51]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[52]  S. Levy,et al.  Hybridoma fusion cell lines contain an aberrant kappa transcript. , 1988, Molecular immunology.

[53]  D. Ish-Horowicz,et al.  Rapid and efficient cosmid cloning , 1981, Nucleic Acids Res..

[54]  R. Huber,et al.  Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI. , 1974, European journal of biochemistry.

[55]  R. Whitley,et al.  Humanized antibodies for antiviral therapy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. Waldmann,et al.  Reshaping a therapeutic CD4 antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Matsushita,et al.  Construction of reshaped human antibodies with HIV-neutralizing activity. , 1991, Human antibodies and hybridomas.